PF-00562271 is a potent and selective inhibitor of focal adhesion kinase (FAK), a protein tyrosine kinase involved in cell adhesion, migration, and survival. It is primarily used in research settings to study the role of FAK in cancer progression, tumor microenvironment signaling, and metastasis. By inhibiting FAK activity, PF-00562271 helps disrupt pathways that support tumor cell survival and resistance to therapy, making it a valuable tool in oncology research. It has been applied in preclinical studies to evaluate the effects of FAK inhibition on tumor growth, particularly in solid tumors such as ovarian, breast, and pancreatic cancers. Additionally, PF-00562271 is used to investigate combination therapies, where FAK inhibition may enhance the efficacy of chemotherapy, targeted therapy, or immunotherapy by modulating the tumor stroma and improving drug delivery. Due to its ability to affect integrin-mediated signaling and angiogenesis, this compound also supports research in cell motility and metastatic mechanisms. Its application remains confined to laboratory and experimental models, with no current clinical use in humans.